杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/11/21 | 1,475 | 1,500 | 1,475 | 1,491 | +24 | +1.6% | 95,500 |
| 2024/11/20 | 1,471 | 1,479 | 1,459 | 1,467 | -17 | -1.1% | 151,500 |
| 2024/11/19 | 1,467 | 1,486 | 1,467 | 1,484 | +17 | +1.2% | 74,000 |
| 2024/11/18 | 1,473 | 1,483 | 1,462 | 1,467 | -6 | -0.4% | 111,800 |
| 2024/11/15 | 1,487 | 1,487 | 1,473 | 1,473 | -11 | -0.7% | 58,900 |
| 2024/11/14 | 1,476 | 1,490 | 1,476 | 1,484 | +11 | +0.7% | 68,300 |
| 2024/11/13 | 1,479 | 1,479 | 1,467 | 1,473 | +5 | +0.3% | 80,100 |
| 2024/11/12 | 1,476 | 1,481 | 1,466 | 1,468 | -9 | -0.6% | 82,000 |
| 2024/11/11 | 1,471 | 1,481 | 1,466 | 1,477 | +2 | +0.1% | 91,300 |
| 2024/11/08 | 1,510 | 1,519 | 1,475 | 1,475 | -45 | -3% | 211,000 |
| 2024/11/07 | 1,505 | 1,529 | 1,505 | 1,520 | +10 | +0.7% | 83,000 |
| 2024/11/06 | 1,501 | 1,520 | 1,498 | 1,510 | +16 | +1.1% | 74,900 |
| 2024/11/05 | 1,518 | 1,518 | 1,494 | 1,494 | -24 | -1.6% | 92,900 |
| 2024/11/01 | 1,500 | 1,531 | 1,496 | 1,518 | +1 | +0.1% | 90,600 |
| 2024/10/31 | 1,499 | 1,519 | 1,497 | 1,517 | +18 | +1.2% | 75,800 |
| 2024/10/30 | 1,488 | 1,504 | 1,488 | 1,499 | +7 | +0.5% | 136,400 |
| 2024/10/29 | 1,487 | 1,496 | 1,483 | 1,492 | +3 | +0.2% | 46,800 |
| 2024/10/28 | 1,480 | 1,495 | 1,472 | 1,489 | +14 | +0.9% | 47,900 |
| 2024/10/25 | 1,487 | 1,487 | 1,468 | 1,475 | -10 | -0.7% | 102,700 |
| 2024/10/24 | 1,493 | 1,498 | 1,484 | 1,485 | -16 | -1.1% | 87,100 |
| 2024/10/23 | 1,497 | 1,503 | 1,493 | 1,501 | +4 | +0.3% | 69,100 |
| 2024/10/22 | 1,520 | 1,520 | 1,495 | 1,497 | -20 | -1.3% | 56,400 |
| 2024/10/21 | 1,522 | 1,525 | 1,515 | 1,517 | +1 | +0.1% | 53,700 |
| 2024/10/18 | 1,508 | 1,523 | 1,506 | 1,516 | +6 | +0.4% | 93,100 |
| 2024/10/17 | 1,502 | 1,517 | 1,502 | 1,510 | +9 | +0.6% | 46,500 |
| 2024/10/16 | 1,493 | 1,511 | 1,485 | 1,501 | ±0 | ±0% | 87,900 |
| 2024/10/15 | 1,505 | 1,511 | 1,495 | 1,501 | -3 | -0.2% | 121,200 |
| 2024/10/11 | 1,505 | 1,518 | 1,503 | 1,504 | -13 | -0.9% | 62,400 |
| 2024/10/10 | 1,520 | 1,520 | 1,508 | 1,517 | +2 | +0.1% | 30,000 |
| 2024/10/09 | 1,513 | 1,522 | 1,506 | 1,515 | +2 | +0.1% | 29,600 |
| 2024/10/08 | 1,521 | 1,525 | 1,510 | 1,513 | -18 | -1.2% | 56,500 |
| 2024/10/07 | 1,541 | 1,541 | 1,527 | 1,531 | +1 | +0.1% | 52,900 |
| 2024/10/04 | 1,523 | 1,536 | 1,522 | 1,530 | +3 | +0.2% | 48,500 |
| 2024/10/03 | 1,528 | 1,535 | 1,518 | 1,527 | +14 | +0.9% | 73,400 |
| 2024/10/02 | 1,506 | 1,518 | 1,500 | 1,513 | +7 | +0.5% | 85,400 |
| 2024/10/01 | 1,514 | 1,514 | 1,499 | 1,506 | -14 | -0.9% | 117,500 |
| 2024/09/30 | 1,506 | 1,522 | 1,504 | 1,520 | -12 | -0.8% | 84,400 |
| 2024/09/27 | 1,540 | 1,547 | 1,530 | 1,532 | -30 | -1.9% | 74,300 |
| 2024/09/26 | 1,542 | 1,564 | 1,538 | 1,562 | +33 | +2.2% | 165,300 |
| 2024/09/25 | 1,525 | 1,535 | 1,514 | 1,529 | +7 | +0.5% | 148,300 |
| 2024/09/24 | 1,519 | 1,528 | 1,508 | 1,522 | +17 | +1.1% | 65,500 |
| 2024/09/20 | 1,513 | 1,522 | 1,497 | 1,505 | -1 | -0.1% | 156,300 |
| 2024/09/19 | 1,513 | 1,519 | 1,504 | 1,506 | -5 | -0.3% | 56,400 |
| 2024/09/18 | 1,516 | 1,518 | 1,498 | 1,511 | +5 | +0.3% | 78,900 |
| 2024/09/17 | 1,532 | 1,532 | 1,497 | 1,506 | -9 | -0.6% | 87,700 |
| 2024/09/13 | 1,517 | 1,519 | 1,506 | 1,515 | -5 | -0.3% | 108,700 |
| 2024/09/12 | 1,528 | 1,541 | 1,512 | 1,520 | +7 | +0.5% | 87,800 |
| 2024/09/11 | 1,540 | 1,540 | 1,509 | 1,513 | -21 | -1.4% | 88,900 |
| 2024/09/10 | 1,541 | 1,558 | 1,534 | 1,534 | -19 | -1.2% | 77,800 |
| 2024/09/09 | 1,550 | 1,555 | 1,532 | 1,553 | -7 | -0.4% | 90,000 |
1～
50
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
